Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

BACKGROUND: Although docetaxel-based chemohormonal therapy (CHT) is one of the standard treatments for castration-resistant prostate cancer (CRPC), pertinent biomarkers and precise mechanisms involved in the resistance for CHT for CRPC remain unknown. We investigated the relationship between chemoho...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Matsuda, Yoshinori, Narita, Shintaro, Nara, Taketoshi, Mingguo, Huang, Sato, Hiromi, Koizumi, Atsushi, Kanda, Sohei, Numakura, Kazuyuki, Saito, Mitsuru, Inoue, Takamitsu, Hiroshima, Yuko, Nanjo, Hiroshi, Satoh, Shigeru, Tsuchiya, Norihiko, Habuchi, Tomonori
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2020
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7333261/
https://ncbi.nlm.nih.gov/pubmed/32293349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06844-y
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires